Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Post by wildbird1on Nov 06, 2018 1:13pm
105 Views
Post# 28931751

Synchronise...

Synchronise...Has I have said many time before, if Genenews expect to increase its test volume and profits, it must first synchronise its diagnosis and billing process with its customer base.
Patients, Doctors, and Insurance Company will not be willing to pay for Genenews tests, unless Genenews billing process work in harmony with their own billing process.

This lack of synchronisation could explain why Genenews said (Quote) ''Test volume was essentially flat '' (End of Quote).

Two PressReleases seem to indicate that the billing process has made good forward progress.
1) PressRelease May 16, 2018...
Genenews said (Quote) '' Lack of received revenu is a result of us having to Restructure and Restart our billing process (End of Quote).
Meaning; After having made some improvements, the billing process has been Restart.

2) PressRelease Aug 15, 2018...
Genenews said (Quote) '' Billing revenue showing Significant increase in Q3 '' (End of Quote).

Note: Q3 will be the first complete quarter with Genenews new and revamped billing process.
With a billing process working properly, even a small increase in test volume ( we prefer a big one) will be considered a big step forward.
Bullboard Posts